Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiarrhythmic agents and proarrhythmia.

G M Chaudhry1, C I Haffajee

  • 1Department of Cardiac Electrophysiology and Pacing, Tufts University School of Medicine, St. Elizabeth's Medical Center, Boston, MA 02135, USA.

Critical Care Medicine
|October 31, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diastolic dysfunction and hypertension.

The New England journal of medicine·2001
Same author

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

Arteriosclerosis, thrombosis, and vascular biology·1997
Same author

Should unipolar pacemaker leads be banned?

Pacing and clinical electrophysiology : PACE·1997
Same author

Effects of oral propafenone on defibrillation and pacing thresholds in patients receiving implantable cardioverter-defibrillators. Propafenone Defibrillation Threshold Investigators.

Journal of the American College of Cardiology·1996
Same author

Zofenopril after anterior myocardial infarction.

The New England journal of medicine·1995
Same author

Sudden death in idiopathic dilated cardiomyopathy: role of ventricular arrhythmias.

Pacing and clinical electrophysiology : PACE·1993
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Attracting Emergency Medicine Graduates to Surgical Critical Care Training Programs.

Critical care medicine·2026
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Beyond a Snapshot: Tracking Family Prognostic Expectations in the ICU.

Critical care medicine·2026
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Plasma Levels of Soluble ST2 Reflect Extrapulmonary Organ Dysfunction and Predict Outcomes in Acute Respiratory Failure: Beware of Potential Confounders.

Critical care medicine·2026
See all related articles

The Vaughn Williams classification categorizes antiarrhythmic drugs by their effects on ion channels. Careful use is essential, as all antiarrhythmics can provoke arrhythmias, especially in patients with cardiac conditions.

Area of Science:

  • Pharmacology
  • Cardiology
  • Electrophysiology

Background:

  • The Vaughn Williams classification is a cornerstone in antiarrhythmic drug categorization.
  • Understanding drug mechanisms is crucial for effective arrhythmia management.
  • The risk of proarrhythmia necessitates careful drug selection and monitoring.

Purpose of the Study:

  • To provide a comprehensive overview of the Vaughn Williams classification of antiarrhythmic agents.
  • To discuss the specific properties, uses, and limitations of each drug class.
  • To highlight the importance of managing proarrhythmia risk.

Main Methods:

  • Literature review of antiarrhythmic drug classifications and mechanisms.
  • Analysis of the Vaughn Williams classification system.

Related Experiment Videos

  • Discussion of clinical applications and risks associated with antiarrhythmic agents.

    • Main Results:

    • Class I agents (sodium channel blockers) are subdivided into Ia, Ib, and Ic, each with distinct clinical roles and risks.
    • Class II (beta-blockers), Class III (prolonging repolarization), and Class IV (calcium channel blockers) agents target different electrophysiological pathways.
    • Lidocaine (Class Ib) is key for ventricular arrhythmias, while Class Ic drugs are cautioned in structural heart disease.
    • Class III agents like amiodarone and sotalol are widely used and under active research.
    • All antiarrhythmic drugs carry a risk of provoking arrhythmias, particularly in vulnerable patients.

    Conclusions:

    • The Vaughn Williams classification provides a framework for understanding antiarrhythmic drug actions and guiding therapy.
    • Risk stratification and careful patient selection are paramount to minimize proarrhythmic effects.
    • Management of proarrhythmia involves correcting electrolyte imbalances and preventing bradycardia during drug metabolism.